Kyung Dong Pharmaceutical Co (011040) Fair Value & Analysis

Healthcare · KR · Market cap 146B KRW

A solid business, screening 21% undervalued on our models.

What matters now

• Solid quality (58/100) at a price below fair value, the discount is the argument here, not the business quality.
• Our model range runs from 4,624 KRW (bear) to 7,706 KRW (bull), base 6,165 KRW. The closer the price sits to the lower half, the larger the margin of safety.
• Quality 58/100 (solid quality) with medium evidence: read the verdict with care.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.

How to read this chart

60‑month range 4,720 KRW – 12,867 KRW · fair‑value band 4,624 KRW – 7,706 KRW · the 5,110 KRW price screens below the 6,165 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 20, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Kyung Dong Pharmaceutical Co (011040) currently trades at 5,110 KRW, while our model-based Fair Value estimate is 6,165 KRW, implying the stock looks roughly 20.6% undervalued today. The Quality Score stands at 58/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, Kyung Dong Pharmaceutical Co generated revenue of 182B KRW at a net margin of 3.6%. Revenue declined 3.8% year over year. It earns a return on equity of 270.9%. Net debt stands at 13.3B KRW. Fundamentals as of Jul 20, 2026

Our scenario range runs from 4,624 KRW (bear case) to 7,706 KRW (bull case); at 5,110 KRW, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 22% below its 52-week high and 6% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -20% fair-value upside, at 21%, 011040 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Asset-Based (6,506 KRW) versus Earnings-Based (2,520 KRW). Highest evidence: Residual Income (76).

Key figures & financial health

Quality Score breakdown

About the company

Kyung Dong Pharmaceutical Co., Ltd. produces and sells specialized and general medicines in South Korea. It offers prescription medicines for liver therapy, antispasmodic, antidiabetic, antiviral, corticosteroid, androgen alopecia, muscle relaxant, antimigraine, vitamin, antifungal, endocrinal, urology, antibacterial, cardiovascular, pain/inflammation, …

Full company description

Kyung Dong Pharmaceutical Co., Ltd. produces and sells specialized and general medicines in South Korea. It offers prescription medicines for liver therapy, antispasmodic, antidiabetic, antiviral, corticosteroid, androgen alopecia, muscle relaxant, antimigraine, vitamin, antifungal, endocrinal, urology, antibacterial, cardiovascular, pain/inflammation, smoking cessation aid, gastrointestinal, antihistamine, CNS, antiobesity, neuropathic, osteoporosis, respiratory, allergy, and arthrifuge categories. The company also provides OTC medicines for pain/inflammation, cardiovascular, hepatic protectors, respiratory, gastrointestinal, calcium agent, antihistamine, antifungal, antibiotic, anti-inflammatory enzyme, dermatologic, antiviral, and contraceptive categories; and APIs and health functional foods, as well as quasi drugs. The company was formerly known as Yuil Trading Company and changed its name to Kyung Dong Pharmaceutical Co., Ltd. in February 1976. Kyung Dong Pharmaceutical Co., Ltd. was founded in 1975 and is headquartered in Seoul, South Korea.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Kyung Dong Pharmaceutical Co reported revenue of 196B KRW in FY2025 versus 178B KRW in FY2021, a compound +2.5%/yr. Reported net income was 8.5B KRW in FY2025, compounding −9.4%/yr from FY2021.

Watch 011040: get an alert when its fair value changes →

Peer Group

Pharmaceuticals · 25 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.